Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases

Background: Lung cancer accounts for about 50% of brain metastases, of which nearly 25% are eligible for neurosurgery, providing a neurological control rate of up to 70% when followed by whole brain radiation therapy. How to manage the primary tung carcinoma remains elusive. Methods: We undertook a retrospective study of consecutive patients who underwent surgical resection for synchronous brain metastases from non-small cell lung cancer in a single institution, to determine overall. survival. and prognostic factors, with particular attention to the treatment of the primary tung tumor. Results: Fifty-one patients underwent surgical resection of synchronous brain metastases from non-small cell lung cancer. Median survival was 13.2 months. Prognosis mainly depended of the treatment of the tung tumor, with a marked survival advantage in the 29 patients receiving a focal treatment (thoracic surgery or radiotherapy), compared to the 22 other patients: median, 1-year, and 2-year survival were 22.5 months, 69%, and 42%, versus 7.1 months, 33%, and 5%, respectively (p < 0.001); response to pre-operative chemotherapy before focal treatment was the main favorable prognostic factor (p = 0.023), and further identified patients who had benefit from resection of the lung tumor, with a significantly better outcome. Conclusions: Chemotherapy, by its therapeutic and prognostic value, may be considered as the cornerstone of the combined medical and surgical therapeutic sequence whereby brain metastasectomy is followed by chemotherapy and further focal treatment of the primary lung tumor in responders to chemotherapy. (c) 2006 Published by Elsevier Ireland Ltd.